Artelo Biosciences, Inc. (ARTL) — Financial statements
Income statement, balance sheet, and cash flow for Artelo Biosciences, Inc. — annual and quarterly history with growth and margin analysis.
| Metric (USD Millions) | 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|---|
| Revenue & Gross Profit | ||||||
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | ||||||
| R&D Expenses | 5↓9.5% | 6↑5.2% | 6↑31.7% | 4↑52.3% | 3 | |
| General & Administrative Expenses | 6↑45.3% | 4↓2.8% | 4↓29.0% | 6↑29.6% | 5 | |
| Selling & Marketing Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| SG&A Expenses | 6↑45.3% | 4↓2.8% | 4↓29.0% | 6↑29.6% | 5 | |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Operating Expenses | 11↑12.8% | 10↑1.8% | 10↓3.5% | 10↑38.2% | 7 | |
| Total Costs & Expenses | 11↑12.8% | 10↑1.8% | 10↓3.5% | 10↑38.2% | 7 | |
| Operating Results | ||||||
| Operating Income | -11↓12.8% | -10↓1.8% | -10↑3.5% | -10↓38.2% | -7 | |
| Depreciation & Amortization | 0.15 | 0.00 | 0.00 | 0.00 | 0.00 | |
| EBITDA | -13↓24.1% | -10↓1.8% | -10↑1.5% | -10↓35.5% | -7 | |
| EBIT | -13↓25.5% | -10↓1.8% | -10↑1.5% | -10↓35.5% | -7 | |
| Interest & Other Income | ||||||
| Net Interest Income | -0.19 | 0.00 | 0.00↑100.0% | -0.00↓250.0% | 0.00 | |
| Interest Income | 0.00 | 0.00 | 0.00↓100.0% | 0.00↑0.0% | 0.00 | |
| Interest Expense | 0.19 | 0.00 | 0.00↓100.0% | 0.01 | 0.00 | |
| Non-Operating Income | 1 | 0.00 | 0.00↑100.0% | -0.21↓5125.0% | -0.00 | |
| Other Income / Expenses | -1↓623.0% | 0.28↓56.0% | 0.64↑214.2% | 0.20↑5000.0% | 0.00 | |
| Income Before Tax | -13↓31.1% | -10↓5.8% | -9↑7.9% | -10↓35.6% | -7 | |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income & EPS | ||||||
| Net Income from Continuing Operations | -13↓31.1% | -10↓5.8% | -9↑7.9% | -10↓35.6% | -7 | |
| Net Income from Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |
| Net Income | -13↓31.1% | -10↓5.8% | -9↑7.9% | -10↓35.6% | -7 | |
| Bottom-Line Net Income | -13↓31.1% | -10↓5.8% | -9↑7.9% | -10↓35.6% | -7 | |
| EPS (Basic) | -5.47↓438.1% | -1.02↑2.9% | -1.05↑10.0% | -1.16↑41.5% | -1.99 | |
| EPS (Diluted) | -5.47↓438.1% | -1.02↑2.9% | -1.05↑10.0% | -1.16↑41.5% | -1.99 | |
| Weighted Average Shares | 2↓75.6% | 10↑8.9% | 9↑527.1% | 1↑127.5% | 0.62 | |
| Weighted Average Diluted Shares | 2↓75.6% | 10↑8.9% | 9↑526.9% | 1↑127.6% | 0.62 | |
* All figures in Millions of USD, except per share data. Growth rates calculated Year-over-Year (YoY). Data source: SEC Filings.